|Slideshows|July 5, 2018

The Brave New World of Inflammation

The immune-brain loop: a world where more and more clinicians boldly go-and thrive-among new discoveries.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

ByGustavo Alva, MD, DFAPA

July 11th 2026

Psychedelics, Orexin Blockers, and More: Inside the Diverse New Pipeline for Depression

ByHeidi Anne Duerr, MPH

July 11th 2026

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

ByCharles Debattista, MD

July 10th 2026

Consensus Guidelines for IV Ketamine: Safe Clinical Practice

BySandhya Prashad, MD

July 9th 2026

Potential of GABAergic Medications in MDD

ByGustavo Alva, MD, DFAPA,Jason Kellogg, MD

July 2nd 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

The Brave New World of Inflammation

Related Content

COMP360 Psilocybin in Treatment-Resistant Depression: Insights From Gus Alva, MD, DFAPA

Psychedelics, Orexin Blockers, and More: Inside the Diverse New Pipeline for Depression

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

Consensus Guidelines for IV Ketamine: Safe Clinical Practice

Potential of GABAergic Medications in MDD

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Vol 43, Issue 7 - Interactive

Beyond Deprescribing: A Formula for Excellent Clinical Care

AI Chatbots and the Erosion of Therapeutic Discomfort

Vagus Nerve Stimulation in Difficult-to-Treat Depression: When Does It Work Best?

Long-Acting Injectables in Schizophrenia: Closing the Gap Between Evidence and Practice